J3P-MC-FTAF: An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502994-40-00

Enrollment

Registered

2023-08-08

Start date

2023-09-04

Completion date

Unknown

Last updated

2025-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

Phase 2a: Change from Baseline in Disease Activity Score – high-sensitivity C-reactive protein (DAS28-hsCRP), Phase 2b: Percentage of Participants Achieving American College of Rheumatology (ACR)50

Interventions

DRUGLY3871801_25g

DRUGPlacebo to match LY3871801

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Phase 2a: Change from Baseline in Disease Activity Score – high-sensitivity C-reactive protein (DAS28-hsCRP), Phase 2b: Percentage of Participants Achieving American College of Rheumatology (ACR)50	—

Countries

Czechia, France, Germany, Hungary, Poland, Slovakia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026